The expectation is that COVID-19 will eventually settle into a winter seasonal pattern like other coronaviruses, but the past ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Research and Development Expenses-- $4,700,000 compared to $5,600,000 during the prior year comparable period. Kodiak PCR ...

Diagnostics' progress on their PCR platform, with key trials in 2025 and commercialization plans by 2026, targeting U.S. and global markets.

Key Points GAAP revenue jumped 413% year over year to $11.8 million in Q2 2025, but fell far short of analyst estimates, with GAAP revenue of $11.8 million missing the consensus of $23.2 million by 49 ...

Seasonal shifts are driving unusual surges in respiratory illnesses in 2025, with COVID-19, influenza, and RSV showing new ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.

RSV is a common respiratory virus that causes mild, cold-like symptoms in healthy adults. Like similar viruses, it infects the nose, throat and lungs, making it difficult to tell apart from other ...